Literature DB >> 12090900

Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.

Silvia G Priori1, Carlo Napolitano.   

Abstract

The novel insights provided by the molecular genetic applied to the study of cardiac arrhythmias have just started to scratch the surface of the complex relationships between the genetic abnormalities of ion channel structure and the susceptibility to life threatening ventricular arrhythmias. These crucial pieces of information that are being gathered may have broader implications than those concerning the relatively restricted field of inherited arrhythmogenic diseases. An area of possible crucial application of the molecular genetic of cardiac ion channels, is the so-called drug-induced Torsade de Pointes (TdP) and acquired Long QT Syndrome. This condition is defined as an abnormal response to the administration of a variety of drugs which, in susceptible subjects, may induce an excessive QT interval prolongation and possibly lead to the onset of life-threatening ventricular tachyarrhythmias (drug-induced TdP). The "proof of concept" that sub-clinical variants of the inherited long QT syndrome may play a causative role has been recently brought to light. However, large population-based studies are still needed in order to quantify the epidemiological relevance of such findings. The future developments in this area of research will lead to the availability of pre-prescription genotyping for the identification of the susceptible subjects and to the development of safer drugs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090900     DOI: 10.1023/a:1015793113771

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  6 in total

1.  Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.

Authors:  Eberhard P Scholz; Edgar Zitron; Claudia Kiesecker; Sonja Lueck; Sven Kathöfer; Dierk Thomas; Slawomir Weretka; Simon Peth; Volker A W Kreye; Wolfgang Schoels; Hugo A Katus; Johann Kiehn; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-14       Impact factor: 3.000

2.  Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.

Authors:  Eberhard P Scholz; Edgar Zitron; Claudia Kiesecker; Sonja Lück; Dierk Thomas; Sven Kathöfer; Volker A W Kreye; Hugo A Katus; Johann Kiehn; Wolfgang Schoels; Christoph A Karle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-09       Impact factor: 3.000

Review 3.  Pharmacogenetic issues in thorough QT trials.

Authors:  Richard S Judson; Benjamin A Salisbury; Carol R Reed; Michael J Ackerman
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  Mechanisms and potential therapeutic targets for ventricular arrhythmias associated with impaired cardiac calcium cycling.

Authors:  Kenneth R Laurita; David S Rosenbaum
Journal:  J Mol Cell Cardiol       Date:  2007-10-25       Impact factor: 5.000

5.  Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.

Authors:  Konstantinos P Letsas; Michalis Efremidis; Stavros P Kounas; Loukas K Pappas; Gerasimos Gavrielatos; Ioannis P Alexanian; Nikolaos P Dimopoulos; Gerasimos S Filippatos; Antonios Sideris; Fotis Kardaras
Journal:  Clin Res Cardiol       Date:  2008-11-24       Impact factor: 5.460

6.  Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.

Authors:  F Fischer; N Vonderlin; C Seyler; E Zitron; B Schernus; H Katus; E Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-12       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.